tetano
Editor, Senior Moderator
Front Immunol
. 2023 Jun 21;14:1212998.
doi: 10.3389/fimmu.2023.1212998. eCollection 2023. Systemic inflammation index, disease severity, and mortality in patients with COVID-19: a systematic review and meta-analysis
Arduino A Mangoni[SUP] 1 2 [/SUP], Angelo Zinellu[SUP] 3 [/SUP]
Affiliations
Introduction: An excessive systemic pro-inflammatory state increases the risk of severe disease and mortality in patients with coronavirus disease 2019 (COVID-19). However, there is uncertainty regarding whether specific biomarkers of inflammation can enhance risk stratification in this group. We conducted a systematic review and meta-analysis to investigate an emerging biomarker of systemic inflammation derived from routine hematological parameters, the systemic inflammation index (SII), in COVID-19 patients with different disease severity and survival status.
Methods: A systematic literature search was conducted in PubMed, Web of Science, and Scopus, between the 1[SUP]st[/SUP] of December 2019 and the 15[SUP]th[/SUP] of March 2023. Risk of bias and certainty of evidence were assessed using the Joanna Briggs Institute Critical Appraisal Checklist and the Grades of Recommendation, Assessment, Development and Evaluation, respectively (PROSPERO registration number: CRD42023420517).
Results: In 39 studies, patients with a severe disease or non-survivor status had significantly higher SII values on admission compared to patients with a non-severe disease or survivor status (standard mean difference (SMD)=0.91, 95% CI 0.75 to 1.06, p<0.001; moderate certainty of evidence). The SII was also significantly associated with the risk of severe disease or death in 10 studies reporting odds ratios (1.007, 95% CI 1.001 to 1.014, p=0.032; very low certainty of evidence) and in six studies reporting hazard ratios (1.99, 95% CI 1.01 to 3.92, p=0.047; very low certainty of evidence). Pooled sensitivity, specificity, and area under the curve for severe disease or mortality were 0.71 (95% CI 0.67 to 0.75), 0.71 (95% CI 0.64 to 0.77), and 0.77 (95% CI 0.73 to 0.80), respectively. In meta-regression, significant correlations were observed between the SMD and albumin, lactate dehydrogenase, creatinine, and D-dimer.
Discussion: Our systematic review and meta-analysis has shown that the SII on admission is significantly associated with severe disease and mortality in patients with COVID-19. Therefore, this inflammatory biomarker derived from routine haematological parameters can be helpful for early risk stratification in this group.
Systematic review registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42023420517.
Keywords: COVID-19; biomarkers; disease severity; inflammation; mortality; risk stratification; systemic inflammation index.
. 2023 Jun 21;14:1212998.
doi: 10.3389/fimmu.2023.1212998. eCollection 2023. Systemic inflammation index, disease severity, and mortality in patients with COVID-19: a systematic review and meta-analysis
Arduino A Mangoni[SUP] 1 2 [/SUP], Angelo Zinellu[SUP] 3 [/SUP]
Affiliations
- PMID: 37415980
- PMCID: PMC10320859
- DOI: 10.3389/fimmu.2023.1212998
Introduction: An excessive systemic pro-inflammatory state increases the risk of severe disease and mortality in patients with coronavirus disease 2019 (COVID-19). However, there is uncertainty regarding whether specific biomarkers of inflammation can enhance risk stratification in this group. We conducted a systematic review and meta-analysis to investigate an emerging biomarker of systemic inflammation derived from routine hematological parameters, the systemic inflammation index (SII), in COVID-19 patients with different disease severity and survival status.
Methods: A systematic literature search was conducted in PubMed, Web of Science, and Scopus, between the 1[SUP]st[/SUP] of December 2019 and the 15[SUP]th[/SUP] of March 2023. Risk of bias and certainty of evidence were assessed using the Joanna Briggs Institute Critical Appraisal Checklist and the Grades of Recommendation, Assessment, Development and Evaluation, respectively (PROSPERO registration number: CRD42023420517).
Results: In 39 studies, patients with a severe disease or non-survivor status had significantly higher SII values on admission compared to patients with a non-severe disease or survivor status (standard mean difference (SMD)=0.91, 95% CI 0.75 to 1.06, p<0.001; moderate certainty of evidence). The SII was also significantly associated with the risk of severe disease or death in 10 studies reporting odds ratios (1.007, 95% CI 1.001 to 1.014, p=0.032; very low certainty of evidence) and in six studies reporting hazard ratios (1.99, 95% CI 1.01 to 3.92, p=0.047; very low certainty of evidence). Pooled sensitivity, specificity, and area under the curve for severe disease or mortality were 0.71 (95% CI 0.67 to 0.75), 0.71 (95% CI 0.64 to 0.77), and 0.77 (95% CI 0.73 to 0.80), respectively. In meta-regression, significant correlations were observed between the SMD and albumin, lactate dehydrogenase, creatinine, and D-dimer.
Discussion: Our systematic review and meta-analysis has shown that the SII on admission is significantly associated with severe disease and mortality in patients with COVID-19. Therefore, this inflammatory biomarker derived from routine haematological parameters can be helpful for early risk stratification in this group.
Systematic review registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42023420517.
Keywords: COVID-19; biomarkers; disease severity; inflammation; mortality; risk stratification; systemic inflammation index.